Chouaid Christos, Giannopoulou Andromachi, Starry Alexandra, Stollenwerk Björn, Bozorgmehr Farastuk
Service de Pneumologie, CHI Créteil, Inserm U955, UPEC, IMRB, Créteil, France.
Amgen (Europe), Health Economics and Outcomes Research, Rotkreuz, Switzerland.
J Med Econ. 2025 Dec;28(1):13-24. doi: 10.1080/13696998.2024.2437324. Epub 2024 Dec 9.
Health-related quality of life (HRQoL) studies in patients with advanced non-small-cell lung cancer (NSCLC) according to mutational status are limited. This study aimed to report real-world evidence on HRQoL outcomes based on mutational status in patients with advanced NSCLC tumors receiving second-line or later (2L+) treatment in France and Germany.
In this real-world, non-interventional, cross-sectional, multicenter, patient-reported outcome (PRO) study conducted in France (15 contributing sites) and Germany (8 contributing sites), physicians enrolled adult patients with locally advanced and unresectable or metastatic NSCLC with known mutation status ( G12C, non-G12C, or wildtype [WT]), who received a 2L + treatment. Study outcomes included sociodemographic characteristics; HRQoL evaluations based on EORTC Global Health Status QoL scores (QLQ-C30) and EQ-5D-5L scores. Data were analyzed descriptively.
Of 156 enrolled patients, data from 149 patients were included in the final analysis (France, = 103; Germany, = 46). Median (quartile [Q]1, Q3) age was 67.0 (61.0, 71.0) years; 56.4% of patients were male. In total, 38.9% ( = 58), 26.2% ( = 39), and 34.9% ( = 52) of patients had tumors with G12C mutation, non-G12C mutation and WT , respectively. Mean (±SD) QLQ-C30 Global Health Status QoL scores were 56.99 (20.30) for the overall population, and 56.03 (22.55), 58.97 (18.67) and 56.57 (19.05) for G12C, non-G12C, and WT subpopulations. In the overall population, moderate-to-extreme problems were reported in all EQ-5D-5L dimensions (range: overall population, 15.5%-39.6%; G12C, 15.6%-46.6%; non-G12C, 7.8%-23.1%; WT, 21.1%-44.2%).
HRQoL was broadly similar across G12C, non-G12C, and WT subpopulations.
根据突变状态对晚期非小细胞肺癌（NSCLC）患者进行的健康相关生活质量（HRQoL）研究有限。本研究旨在报告在法国和德国接受二线或更晚期（2L+）治疗的晚期NSCLC肿瘤患者中，基于突变状态的HRQoL结果的真实世界证据。
在这项在法国（15个参与地点）和德国（8个参与地点）进行的真实世界、非干预性、横断面、多中心、患者报告结局（PRO）研究中，医生纳入了已知突变状态（G12C、非G12C或野生型[WT]）的局部晚期、不可切除或转移性NSCLC成年患者，这些患者接受了2L+治疗。研究结局包括社会人口统计学特征；基于欧洲癌症研究与治疗组织（EORTC）全球健康状况生活质量评分（QLQ-C30）和EQ-5D-5L评分的HRQoL评估。对数据进行描述性分析。
在156名入组患者中，149名患者的数据纳入最终分析（法国，n = 103；德国，n = 46）。中位（四分位数[Q]1，Q3）年龄为67.0（61.0，71.0）岁；56.4%的患者为男性。总体而言，分别有38.9%（n = 58）、26.2%（n = 39）和34.9%（n = 52）的患者肿瘤具有G12C突变、非G12C突变和WT。总体人群的平均（±标准差）QLQ-C30全球健康状况生活质量评分为56.99（20.30），G12C、非G12C和WT亚组分别为56.03（22.55）、58.97（18.67）和56.57（19.05）。在总体人群中，EQ-5D-5L所有维度均报告了中度至重度问题（范围：总体人群，15.5%-39.6%；G12C，15.6%-46.6%；非G12C，7.8%-23.1%；WT, 21.1%-44.2%）。
G12C、非G12C和WT亚组的HRQoL大致相似。
